NCT00430261

Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma

Phase II Trial of Sunitinib in Bronchoalveolar Carcinoma or Never-Smokers With Any Lung Adenocarcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Swedish Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label study of a new oral drug for advanced stage (IIIB or IV) lung cancer. The cancer must be EITHER bronchoalveolar carcinoma (BAC) type, or if the patient is a never-smoker (less than 100 cigarettes lifetime) the cancer can be any type of adenocarcinoma.

Detailed description

To participate in this study, patients must have disease that can be measured on a CT scan. Brain metastases are OK if stable. Pregnant and/or nursing women may not participate. This drug has been approved by the FDA for the treatment of advanced renal cell cancer and a certain type of stomach/intestinal cancer. Its efficacy in lung cancer in currently unknown. Common side effects include fatigue, nausea, diarrhea, skin reaction, and decreased blood counts.

Conditions

• Lung Cancer
• Adenocarcinoma

Interventions

Type	Name	Description
DRUG	sunitinib	50mg po qd x 4 weeks on followed by 2 weeks off for a 6 week cycle.

Timeline

• Start date: 2007-01-01
• Primary completion: 2010-10-01
• Completion: 2010-10-01
• First posted: 2007-02-01
• Last updated: 2010-10-06

Locations

1 site across 1 country: United States